Is PolyPid Ltd. (PYPD) a Buy, Sell, or Hold?
NASDAQ : PYPD
PolyPid Ltd.
$4.71 USD
-$0.02 (-0.42%)
- Volume
- 196.46K
- Average Volume
- 169.93K
- Market Capitalization
- $89.88M
- P/E Ratio
- -2.47
- Dividend Yield
- 0.00%
- Price Target
- $12.50
- Year High
- $5.73
- Year Low
- $3.06
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.78
Company Overview
NASDAQ
Dikla Czaczkes Akselbrad
Biotechnology
Healthcare
PYPD
72
IL
USD
Liquidity Metrics
0.27
1.78
1.63
1.29
0.00
Sales & Valuation
-$
0.00
11.76
0.00
0.00
Profitability
-$2.09
-$34.17M
0.00%
0.00%
-241.96%
-175.52%
P/E Metrics
-2.47
-0.03
-0.03
Analyst Price Target & Rating
$12.50
$13.00
$12.00
1/5
9 Analysts
-62.32%
Financial Health Scores
-22.73
3/9
$5.51M
$19.16M
$10.38M
-$33.09M
Key Metrics (TTM)
$83.52M
0.00
-2.56
1.78
-241.96%
-114.31%
-32.43%
0.00%
0 days
Company Executives
| Name | Title |
|---|---|
| Jean-Marc Hagai | Chief Commercial Officer |
| Jonny Missulawin | Chief Financial Officer |
| Ori Warshavsky | Chief Operating Officer - US |
| Dalit Hazan | Deputy Chief Executive Officer and Executive Vice President of R&D, Clinical & Regulatory Affairs |
| Maria Rubin | Executive Vice President of Operations |
| Nurit Tweezer-Zaks | Chief Medical Officer |
| Dikla Czaczkes Akselbrad | Chief Executive Officer & Director |
| Rivi Lev-ari | Vice President of Human Resource |
| Tal Vilnai | General Counsel & Corporate Secretary |
Poll Results
No votes yet today — be the first to share your view!
About PolyPid Ltd. (NASDAQ:PYPD) Stock
PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions. These solutions are based on its proprietary polymer-lipid encapsulation matrix (PLEX) platform, with the goal of addressing significant unmet medical needs. The company's leading product candidate, D-PLEX100, is currently undergoing Phase III clinical trials. It is being evaluated for its efficacy in preventing surgical site infections (SSIs) following both sternal (bone) and abdominal (soft tissue) procedures. Established in 2008, PolyPid Ltd. is headquartered in Petah Tikva, Israel. ...
PolyPid Ltd. (PYPD) Q2 2026 Earnings Call Transcript
2026-08-12 14:17:17
PolyPid Ltd. (PYPD) Q2 2026 Earnings Call Transcript
PolyPid Q2 Earnings Call Highlights
2026-08-12 12:04:32
PolyPid NASDAQ: PYPD said its second-quarter 2026 was marked by the FDA's acceptance of its new drug application for D-PLEX100 and a commercialization agreement with Azurity Pharmaceuticals covering the United States and Canada.
PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results
2026-08-12 07:30:00
FDA Accepted D-PLEX₁₀₀ NDA with Priority Review; PDUFA Goal Date of November 28, 2026, Approximately One Quarter Ahead of Previously Communicated Guidance
2026-07-30 08:00:00
PETACH TIKVA, Israel, July 30, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that it will report its second quarter 2026 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, August 12, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.
PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀
2026-07-29 08:30:00
PDUFA target action date of November 28, 2026, approximately one quarter ahead of Company's previously communicated guidance
PolyPid, Azurity sign surgical site infection drug deal
2026-07-21 07:31:52
Israeli biotech PolyPid said on Tuesday it had agreed a deal with Azurity Pharmaceuticals to commercialise a drug aimed at preventing surgical site infections in the U.S. and Canada, under which it could receive more than $320 million.
2026-07-21 07:30:00
PolyPid to potentially receive over $320 million in upfront and milestone payments, including $30 million in upfront and near-term milestone payments, plus tiered royalties ranging from mid-teen to mid-twenties percentagesAzurity, a private global pharmaceutical company, to commercialize D-PLEX100 upon approval in the U.
2026-07-21 07:30:00
PETACH TIKVA, Israel, July 21, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins, today announced that it has entered into an exclusive commercial partnership agreement (the “Agreement”) with Azurity Pharmaceuticals (“Azurity”), a privately held specialty pharmaceutical company, for the commercialization of D-PLEX100 in the United States and Canada for the prevention of surgical site infections (“SSIs”).
Frequently Asked Questions
-
What is the current PolyPid Ltd. (PYPD) stock price?
-
PolyPid Ltd.(NASDAQ:PYPD) stock price is $4.71 in the last trading session. During the trading session, PYPD stock reached the peak price of $5.73 while $3.06 was the lowest point it dropped to. The percentage change in PYPD stock occurred in the recent session was --0.42% while the dollar amount for the price change in PYPD stock was -$0.02.
-
PYPD's industry and sector of operation?
-
The NASDAQ listed PYPD is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of PYPD?
-
Jean-Marc Hagai | Chief Commercial Officer
Jonny Missulawin | Chief Financial Officer
Ori Warshavsky | Chief Operating Officer - US
Dalit Hazan | Deputy Chief Executive Officer and Executive Vice President of R&D, Clinical & Regulatory Affairs
Maria Rubin | Executive Vice President of Operations -
How many employees does PYPD have?
-
Number of PYPD employees currently stands at 72. PYPD operates from 18 Hasivim Street, Petah Tikva, HM 4959376, IL.
-
Link for PYPD official website?
-
Official Website of PYPD is: https://www.polypid.com
-
How do I contact PYPD?
-
PYPD could be contacted at phone #972 7 4719 5700 and can also be accessed through its website. PYPD operates from 18 Hasivim Street, Petah Tikva, HM 4959376, IL.
-
How many shares of PYPD are traded daily?
-
The average number of PYPD shares traded daily for last 3 months was 169.93K.
-
What is the market cap of PYPD currently?
-
The market value of PYPD currently stands at $89.88M with its latest stock price at $4.71